Copyright © IMARC Service Pvt Ltd. All Rights Reserved Global Biosimilar Market Report and Forecast Till 2023

IMARC is a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results. Report Description About IMARC Group

Report Description Report Description and Highlights Biosimilar Market Report By Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim and Others), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology and Others), Manufacturer Type, Region The global biosimilar market has witnessed a double-digit growth over past few years. Factors such as increasing prevalence of lifestyle diseases, savings for governments and third party-payers, and incentives for pharmacists have been proactive in propelling the market growth. Market Overview: According to the recent report by IMARC Group, entitled “Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast ”, the global biosimilar market size was estimated to be US$ 2.9 Billion in 2017, growing at a CAGR of more than 36% during Biosimilars, also known as subsequent entry biologics (SEBs) or follow-on biologics, refer to FDA- approved biotherapeutic products which are similar to their reference biologics. Biosimilars can only be manufactured after the patent of the reference product expires. The demand for biosimilars has been increasing in recent years as they help in reducing the overall cost of the treatment for a variety of chronic diseases including cancers, autoimmune diseases, kidney failure, diabetes, CVDs, haematological disorders, infectious diseases, rheumatoid arthritis, growth hormone deficiency, etc.

Report Description Report Description and Highlights Global Biosimilar Market Drivers: Recent patent expiries of a large number of blockbuster biological drugs such as Humira, Remicade, MabThera, Enbrel, etc. have majorly boosted the growth of the biosimilar market. Another major growth-inducing factor is ageing population which has led to a rise in the prevalence of non- communicable diseases. Further, high costs of innovator biologics, especially monoclonal antibodies (mAbs), have encouraged several governments across the globe to promote the usage of biosimilars. For instance, European countries like the Netherlands, Denmark and Germany have established strategic models for discount pricing and introduced numerous incentive programs. Apart from this, biosimilars do not require extensive marketing as the safety and efficacy profile of biologics has already been established. This has resulted into the low cost of these drugs in comparison to their branded counterparts, in turn, spurring their demand worldwide. Due to the abovementioned factors, the market is projected to expand at a CAGR of more than 30% during , registering a value of US$ 15.6 Billion by Biosimilar Market Segmentation: Market Segmentation by Molecule Request for a free sample report:

Sample Figure: Global: Biosimilar Market Forecast: Value (in Million US$), Market Forecast

Report Description Market Segmentation o Infliximab, o Insulin Glargine, o Epoetin Alfa, o Etanercept, o Filgrastim o Others Based on molecule type, Infliximab represents the largest segment, accounting for the majority of the total market share. Other major categories include Insulin Glargine, Epoetin Alpha, Ethanercept, Filgrastim, Somatropin, Rituximab and Follitropian Alfa. Market Segmentation by Type of Manufacturing In-house Manufacturing Contract Manufacturing On the basis of type of manufacturing, the market has been bifurcated into in-house and contract manufacturing. Currently, in-house manufacturing holds around three-fourth of the total share, representing the dominant segment. This method enables the manufacturers to monitor every step of the biosimilars’ production process and eliminates both shipping and delivery costs.

Report Description Market Segmentation Market Segmentation by Region Europe United States Japan India South Korea Region-wise, Europe is the leading market with more than a half of the global share. This can be attributed to the large ageing population in the region. Besides Europe, other major regions include the United States, India, Japan and South Korea. Market Segmentation by Indication Auto-Immune Diseases Blood Disorder Diabetes Oncology Growth Deficiency For More information, Please Visit:

North America Latin America Europe Middle East and Africa Asia- Pacific Regional Segmentation

Report Description Market Segmentation Female Infertility The market has also been segregated on the basis of indication as autoimmune diseases, oncology, diabetes, blood disorder, growth deficiency and female infertility. Amongst these, autoimmune diseases account for around a half of the global share. Competitive Landscape: The competitive landscape of the market has also been examined with some of the key players. Sandoz International GmbH, Pfizer Inc., Teva Pharmaceutical Industries Limited, Celltrion Inc., Biocon Limited, Samsung Biologics, Amgen, Stada Arzneimittel Ag Others

Report Description Market Segmentation In case you have a very specific customized or specific niche needs, we can work around the scope of work and assist you with the tailor made solution. The topics covered could be technology, markets, competition, pricing trends, P&L analysis, cost analysis, price bench marking or it could also be supplementing you with the weekly or fortnight reports.

Our Team Comes From Some of the Top Universities Globally. 5% Others Average Experience of 7+ Years 60% Engineering and Science 35% Business Studies Over 2000 Independent Consultants from different sectors. Team Profile

A partial List of our Clients We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients

A partial List of our Clients We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients

Report Description Report Description and Highlights © 2018 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

FOR MORE DETAILS Visit us at : Stay With Us: TELEPHONE: Contact Us